Related Experiment Videos
Why cyclooxygenase-2 inhibition plus chemotherapy?
1Indiana University, Indianapolis, Indiana 46202, USA. chsweene@iupui.edu
American Journal of Clinical Oncology
|August 7, 2003
Summary
New research explores targeting Cyclooxygenase-2 (COX-2) to improve cancer treatment. Combining COX-2 inhibition with chemotherapy shows potential for better outcomes and supportive care, warranting further clinical trials.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Cyclooxygenase-2 (COX-2) is implicated in various epithelial tumors, correlating with poor prognosis.
- COX-2 plays a role in cancer progression and resistance to chemotherapy.
- Targeting COX-2 may offer supportive care benefits for cancer patients.
Purpose of the Study:
- To describe the rationale for a Phase II trial investigating specific COX-2 inhibition combined with chemotherapy.
- To evaluate the toxicity and efficacy of this combined therapeutic approach.
Main Methods:
- The study outlines the design for a Phase II clinical trial.
- The trial will assess the safety and effectiveness of specific COX-2 inhibitors in conjunction with standard chemotherapy.
Main Results:
- Preclinical data suggest COX-2 as a viable therapeutic target.
- The Phase II trial aims to define the toxicity profile and preliminary efficacy of the combination therapy.
Conclusions:
- Specific COX-2 inhibition combined with chemotherapy presents a promising avenue for cancer treatment.
- Further Phase III trials are necessary to confirm improved patient outcomes and establish a favorable safety profile for COX-2 targeted therapy.